A part of Watch Media

MedWatchThursday5 October 2023

  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
MedWatchThursday5 October 2023
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
Medtech

Ambu to raise USD 212m in new capital

While Ambu has had an extraordinary start to the year due to Covid-19, the Danish medtech firm now plans to raise a large amount of extra capital for further initiatives that can accelerate growth.
Photo: Ambu / PR
Photo: Ambu / PR
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

Ambu plans to raise DKK 1.3bn (USD 212m) in fresh capital through the private placement of new and existing shareholders in an accelerated bookbuilding process, which Ambu announced on Wednesday morning, on which occasion the medtech firm presented its fiscal report for Q1 of the staggered financial year 2020/20201, which in many ways turned out even better than analysts expected.

This move is a way of strengthening Ambu's capital base, which can provide the firm with more strategic and operational flexibility, writes the company in the announcement.

"Growth of the single-use endoscopy market has accelerated on the back of an increased awareness of contamination levels and technological advances, and the COVID-19 pandemic has further increased the receptiveness to single-use endoscopy," writes Ambu in the statement.

Ambu aspires to become the most innovative player on the market for single-use endoscopies, and in order to reach this goal and attain more flexibility the firm sees it as necessary to raise DKK 1.3bn.

The proceeds will go towards paying back debts, according to the company announcement.

Financial institutions Danske Bank, J.P. Morgan AG and Nordea Danmark are acting as joint global coordinators and joint bookrunners for this offering, according to Ambu.

Would you like to receive the latest news from MedWatch directly in your e-mail inbox? Sign up for our free English newsletter below.

Germany to start registering single-use scopes – Ambu to take advantage 

WS Audiology plans to beat competition by way of younger target group – launches hearing aid designed like Apple earbuds 

Coloplast CEO urged to take action: Release the billions! 

Ambu lands new single-use endoscope contract with US GPO 

 

Share article

Related articles:

  • Photo: Ambu / PR

    Germany to start registering single-use scopes – Ambu to take advantage

    For subscribers

  • Photo: WS Audiology / PR

    WS Audiology plans to beat competition by way of younger target group – launches hearing aid designed like Apple earbuds

    For subscribers

  • Coloplast CEO Kristian Villumsen | Photo: Stine Bidstrup/ERH

    Coloplast CEO urged to take action: Release the billions!

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Foto: Staff/Reuters/Ritzau Scanpix
Pharma & biotech

Novo Nordisk suffers Wegovy defeat to Viatris in patent court

It is the copy producer Viatris that has challenged three of the patents behind Novo Nordisk’s GLP-1 molecule Semaglutide.
  • Novo Nordisk's semaglutide to be studied for positive effect on alcoholics
  • FDA approves Novo Nordisk drug to treat rare condition


Photo: Mike Blake
Pharma & biotech

Eli Lilly's head of diabetes and obesity retires

For subscribers



Pharma & biotech

DNB expects ALK's tablet sales to recover in 2024

For subscribers


Karin Absalonsen, now-former chairperson of Immunitrack and partner at Hannibal Innovation | Foto: Pr
Pharma & biotech

Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees

For subscribers


Foto: Novo Nordisk / Pr
Pharma & biotech

Pharmaceutical industry to grow 4% annually towards 2030

For subscribers


Photo: Stine Bidstrup
Pharma & biotech

Zealand Pharma CEO: "We've never been stronger"

For subscribers


  • Photo: Tom Little

    Investment bank: Novo Nordisk's patent victory is a small win as price negotiations loom

    The market’s attention is more focused on public health insurance Medicare’s new price negotiations under the so-called Inflation Reduction Act.

    For subscribers


  • Photo: Tom Little

    FDA approves Novo Nordisk drug to treat rare condition

    The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

    For subscribers


  • Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Photo: Liselotte Plenov / Fotorummet / Pr

    Fujifilm expands management with former Leo executive

    The contract manufacturer has hired a chief people officer with immediate effect.

    For subscribers


  • Photo: Andrew Kelly/Reuters/Ritzau Scanpix

    Low share price may knock Galecto off the stock exchange

    Nasdaq has requested that the biotech company raise its share price to above USD 1.

    For subscribers


  • Photo: Mike Segar/Reuters/Ritzau Scanpix

    Snack maker keeps an eye on Novo Nordisk's obesity drug

    ”As with anything that could potentially impact our business, we’re looking at it,” says the former Kellogg’s CEO.

  • Photo: Yuriko Nakao/Reuters/Ritzau Scanpix

    Olympus appoints new chief medical officer

    The new medical director is brought in from Medtronic. 

    For subscribers


Further reading

Photo: Mike Blake
Pharma & biotech

Eli Lilly's head of diabetes and obesity retires

Mike Mason announces that he will retire at the end of the year after 34 years with the company.

For subscribers



Karin Absalonsen, now-former chairperson of Immunitrack and partner at Hannibal Innovation | Foto: Pr
Pharma & biotech

Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees

The amount of cash that Eli Lilly had to fork out to gain dominion of Immunitrack has been kept under wraps.

For subscribers



Novo Nordisk's manufacturing facility in Clayton, the US. | Photo: Novo Nordisk/pr
Pharma & biotech

Novo Nordisk facility in the US allegedly receives FDA notice

The FDA has reportedly notified the company’s management of problematic conditions.

For subscribers


Foto: Staff/Reuters/Ritzau Scanpix
Pharma & biotech

Novo Nordisk suffers Wegovy defeat to Viatris in patent court

It is the copy producer Viatris that has challenged three of the patents behind Novo Nordisk’s GLP-1 molecule Semaglutide.


Photo: Tom Little
Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

For subscribers



Photo: Staff
Pharma & biotech

Novo Nordisk to sell Wegovy in the UK at a fraction of the US price

The price of weight loss drug Wegovy in the UK is completely different price than the in the US.

For subscribers


Jobs

  • Senior QA Specialists (GMP or GCP)

  • Audit & Supplier Manager

  • VP of Software Development, Perfusion Tech

  • Director, Head of Antibody Technology

  • QA/RA Manager

  • Project Director, HR & ESG

  • Chemist for Incoming Materials in QC department

  • Scientist - Bioanalysis, Biologics

  • Senior Legal Councel

  • Senior CMC Specialist, Upstream Processing, Genmab

  • Discovery Project Leader, Principal Scientist

  • Clinical Trial Manager

  • Clinical Supply Manager

  • Qualified Person to AJ Vaccines

  • Global Medical Manager

See all jobs

Latest news

  • Novo Nordisk suffers Wegovy defeat to Viatris in patent court –
  • Pharmaceutical industry to grow 4% annually towards 2030 –
  • Zealand Pharma CEO: "We've never been stronger" –
  • Eli Lilly's head of diabetes and obesity retires –
  • DNB expects ALK's tablet sales to recover in 2024 –
  • Eli Lilly makes acquisition in Denmark: Takes over company with 12 employees –
  • Investment bank: Novo Nordisk's patent victory is a small win as price negotiations loom –
  • Novo Nordisk's semaglutide to be studied for positive effect on alcoholics –
  • Olympus appoints new chief medical officer –
  • Low share price may knock Galecto off the stock exchange –
See all

Jobs

  • Senior QA Specialists (GMP or GCP)

  • Audit & Supplier Manager

  • VP of Software Development, Perfusion Tech

  • Director, Head of Antibody Technology

  • QA/RA Manager

  • Project Director, HR & ESG

  • Chemist for Incoming Materials in QC department

  • Scientist - Bioanalysis, Biologics

  • Senior Legal Councel

  • Senior CMC Specialist, Upstream Processing, Genmab

  • Discovery Project Leader, Principal Scientist

  • Clinical Trial Manager

  • Clinical Supply Manager

  • Qualified Person to AJ Vaccines

  • Global Medical Manager

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

  • About MedWatch

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Banner Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved